Lipochip for the genetic diagnosis of familial hypercholesterolaemia
Ellery B, Mundy L, Hiller JE
Record ID 32010001657
English
Authors' recommendations:
Studies to date continue to show that LIPOchip® is an efficient tool in the diagnosis of FH among high risk populations, certainly favourable above clinical diagnosis alone. More studies comparing different genetic methods for FH determination may aid clinicians to make informed decisions about which tests provide the most accurate and efficient results. Long term outcomes have not been investigated; however, LIPOchip® has performed as an inexpensive technology in the detection of FH.There is an obvious clinical need for the accurate and rapid diagnosis of familial hypercholesterolaemia, which the LIPOchip® technology appears to satisfy. Clinicians may choose to adopt this maturing technology as a first choice diagnostic tool in place of the more labour intensive DNA sequencing and therefore no further review on behalf of HealthPACT is required. HealthPACT has recommended that this summary be disseminated to the jurisdictions and to the Human Genetics Advisory group.
Details
Project Status:
Completed
Year Published:
2010
URL for published report:
Not Available
English language abstract:
An English language summary is available
Publication Type:
Not Assigned
Country:
Australia
MeSH Terms
- Hyperlipoproteinemia Type II
Keywords
- familial hypercholesterolaemia
- LIPOchip three-tiered system
Contact
Organisation Name:
Adelaide Health Technology Assessment
Contact Address:
School of Public Health, Mail Drop 545, University of Adelaide, Adelaide SA 5005, AUSTRALIA, Tel: +61 8 8313 4617
Contact Name:
ahta@adelaide.edu.au
Contact Email:
ahta@adelaide.edu.au
Copyright:
Adelaide Health Technology Assessment (AHTA)
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.